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Abstract Background There are concerns about main-
taining appropriate clinical staffing levels in Emergency
Departments. Pharmacists may be one possible solution.
Objective To determine if Emergency Department atten-
dees could be clinically managed by pharmacists with or
without advanced clinical practice training. Setting
Prospective 49 site cross-sectional observational study of
patients attending Emergency Departments in England.
Method Pharmacist data collectors identified patient
attendance at their Emergency Department, recorded
anonymized details of 400 cases and categorized each into
one of four possible options: cases which could be man-
aged by a community pharmacist; could be managed by a
hospital pharmacist independent prescriber; could be
managed by a hospital pharmacist independent prescriber
with additional clinical training; or medical team only
(unsuitable for pharmacists to manage). Impact indices
sensitive to both workload and proportion of pharmacist
manageable cases were calculated for each clinical group.
Main outcome measure Proportion of cases which could be
managed by a pharmacist. Results 18,613 cases were
observed from 49 sites. 726 (3.9%) of cases were judged
suitable for clinical management by community pharma-
cists, 719 (3.9%) by pharmacist prescribers, 5202 (27.9%)
by pharmacist prescribers with further training, and 11,966
(64.3%) for medical team only. Impact Indices of the most
frequent clinical groupings were general medicine (13.18)
and orthopaedics (9.69). Conclusion The proportion of
Emergency Department cases that could potentially be
managed by a pharmacist was 36%. Greatest potential for
pharmacist management was in general medicine and
orthopaedics (usually minor trauma). Findings support the
case for extending the clinical role of pharmacists.
Keywords Clinical pharmacy  Emergency Department 
Pharmacist  Pharmacist training
Impacts of practice
• Advanced trained clinical pharmacists may support the
clinical workload of Emergency Departments.
• Up to 8% of patients attending Emergency Departments
may be clinically managed by pharmacists with exist-
ing training, and a further 28% after additional clinical
training.
• To ensure the highest impact on clinical workload
advanced training of pharmacists should focus on
general medicine and orthopaedics (usually minor
trauma).
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Introduction
Background
At present there are concerns about maintaining appropri-
ate clinical staffing levels in Emergency Departments (ED)
in England [1] and in other countries [2, 3]. One possible
solution is the extension of clinical activity performed by
non-medical staff—including pharmacists [4]. Subsidiary
clinical management of ED attendees may support patient
through-put, relieve pressure on medical staff and reduce
costs.
Extending the pharmacist’s role in ED may also con-
tribute to error minimization [3, 5]. Publications concern-
ing pharmacists working within ED are usually focused on
drug management, their role in ‘Rapid Response Teams’ or
their role in Medical Admission Units, the usual admission
route following ED [6, 7].
Importance
Over the last 10 years there has been an expansion of
United Kingdom (UK) Universities training pharmacists
and there is now a surplus of registered pharmacists in
England [8].
Since 2006 clinical pharmacists in UK have been able to
undertake further training to become fully independent
prescribers [9]. In March 2015 there were 2191 pharma-
cists with independent prescribing rights registered with
the national regulatory body, the General Pharmaceutical
Council. Clinical pharmacist independent prescribers may
benefit from further training beyond prescribing, and are
eligible to take a recently introduced educational pro-
gramme to become Advanced Clinical Practitioners (ACP)
[10]. Pharmacists with ACP training can conduct compre-
hensive physical examinations, request and interpret tests,
diagnose and treat illnesses and injuries, and counsel
patients on preventive healthcare. The proposed extended
role for pharmacists with ACP training is not intended to
replace the existing workforce, but to become a comple-
mentary group of clinicians who can diversify and become
part of a fully integrated consultant-led team in the ED
[11].
Aim of the study
To determine the potential for pharmacists to clinically
manage patients within ED; and from this investigation
identify the clinical areas most likely to be impacted by
extending the role of the pharmacists; and identify the
training needs for the future ED workforce of pharmacists.
Ethics approval
The study was commissioned and approved by Health
Education England (West Midlands). The Research and
Development departments of the data capture sites con-
firmed that the study was classified as service development,
and therefore further approval was not required.
Method
Study design and setting
Multi-site, cross-sectional observational study conducted
by independent prescribing pharmacist data collectors
within 49 hospital sites in England (primary categoriza-
tion). A range of hospitals from the regions of England
participated in the study: Buckinghamshire and Oxford-
shire (n = 4), East Anglia (n = 4), East Midlands (n = 4),
London (n = 8), North East (n = 4), North West (n = 8),
South (n = 2), South East (n = 4), South West (n = 5),
West Midlands (n = 2), Yorkshire and Humber (n = 4).
All hospitals were type 1 Emergency Departments—con-
sultant led 24 hour service with full resuscitation facilities
and designated accommodation for the reception of acci-
dent and emergency patients. Only two West Midland
hospitals were included in the study as two other hospitals
had already taken part in the pilot project that was used to
validate and refine the methodology of data capture [12].
Selection of participants
A representative sample of cases was taken from a cross-
section of attendees and care pathways at each study site to
reflect the usual workload characteristics of the depart-
ments. An independent prescriber pharmacist (IPP) based
at the participating hospital was seconded from their usual
role to undertake data capture within the ED at their site.
Each IPP was asked to observe 400 ED attendee cases that
would represent the typical case-mix of patients and record
anonymized details of the case. Patients of all age ranges
and presentations who attended ED at the time of the data
collection were included in the study.
Interventions
This study was non-interventional and was a cross-sec-
tional observational study where pharmacists were
observing a representative sample of ED attendees, and
assessing each for the potential of the case to be clinically
managed by pharmacists with or without advanced clinical
practice training.
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Methods and measurements
Each data capture pharmacist was asked to record anon-
ymized details of the cases and categorize each into one of
four possible categories. They made this choice according
to their own experience and knowledge of pharmacist
training and range of competencies. The data capture
instrument had been previously validated by a smaller pilot
project based in the West Midlands [12]. An anonymized
data-set for each attendee was recorded and managed using
Microsoft Excel 2010 and a purpose built Microsoft Access
database. Each site was requested to provide anonymized
details of 400 cases.
The four categorizations were applied to each of the
cases recorded during the study. These were:
• CP, community pharmacist could be managed by a
community pharmacist (CP) working in a community
pharmacy. (That is: attendance at ED was not neces-
sary). CPs in the UK have at least 5 years training.
• IP, independent prescriber pharmacist could be man-
aged by a hospital pharmacist with Independent
Prescriber status. IPs have further post-registration
training that gives them some clinical assessment skills
and allows them to be fully independent prescribers. IPs
have at least 8 years training/experience.
• IPT, independent prescriber pharmacist with additional
training could be managed by a hospital pharmacist with
Independent Prescriber status and additional clinical
training, aligned to the Advanced Clinical Practice
training pathway. The study was designed to identify
what further training—in addition to the skills acquired
from the General Pharmaceutical Council accredited
independent prescribing course—would be most useful
to support clinical management of ED attendees.
• MT, medical team unsuitable for pharmacist manage-
ment—requires medical team management.
Primary categorization of harvested presentations was
undertaken by the data capture independent prescriber
pharmacists (IPPs, n = 63) at the study sites at the time of
the presentation. These staff had access to the full patient
details at the point of data capture. The pharmacists were
chosen to do the primary review of cases, as they were the
best placed health care professional with an understanding
of the competencies of a pharmacist independent pre-
scriber, and what additional skills they would need to
extend their role.
Outcomes
The primary outcome measure was the proportion of ED
cases that could be managed by a pharmacist with or
without further ACP training.
The secondary outcome measures:
• Identification of the clinical areas that are most likely to
be impacted by extending the role of the pharmacist.
• Identification of training needs for future ED pharma-
cists—via content analysis of the IPT training needs
described by the primary categorizer pharmacists.
Analysis
All data were recorded on Microsoft Excel 2010, managed
using Microsoft Access 2010 and exported into IBM SPSS
version 21 and Minitab 17 for descriptive and statistical
analysis.
Qualitative analysis of the IPT training needs specified
by the primary categorizer was done via NVIVO version
10, and qualitative content analysis on the recorded text of
training needs based on case observations [13]. The train-
ing need themes identified and coded from the recorded
text, were allocated into one of four main categories:
clinical examination and assessment, diagnosis skills,
medical management, and treatment and training course
components. The frequency of occurrences for each theme
of training needs were determined. The training needs were
coded by a trained research assistant (LM) and confirmed
by a research pharmacist (CH) for consistency.
Primary categorizations (on-site, by IPPs, in real-
time)
Summary statistics for each category—CP, IP, IPT and MT
were calculated.
Secondary categorizations (off-site, by ED
physicians, ED nurses and pharmacists)
Secondary categorization was undertaken by reference to
the anonymized summary information recorded for this
purpose by the data capture IPPs. The data-set included
age, presenting complaint and clinical grouping. The
clinical cases were recorded and randomised using a pur-
pose designed Microsoft Access database. The database
was programmed to generate 800 cases of ED attendees for
each secondary categorizer to consider—who was asked to
categorize each into the four categories defined within the
study (CP, IP, IPT, MT). The primary categorization for
the cases were removed prior to secondary categorization.
Blind secondary categorization was undertaken by 15
pharmacists, 6 ED physicians and 4 ED nurses. This was
completed personally by each of the secondary categoriz-
ers, without consultation, and without reference to cate-
gories assigned by others. Summary secondary
categorization is expressed either as cases (based on a
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mean of all categorizations awarded for an individual
case—type A calculation) or counts (summation of all
categorizations—type B calculation).
The primary and secondary categorizations were com-
pared and the level of agreement between the two identified
across the four categories (presumed to be non-ordered/not
ranked)—assessed using a kappa statistic via Minitab
version 17. A non-ranked categorical kappa statistic was
considered to be most appropriate in this case because,
although there was increasing levels of training (commu-
nity pharmacist least, through to medical team the most),
the consistency of such differences are not clear.
Regional variation
The categorization data for both the primary and secondary
data was split into regions across England for regional
variation analysis.
Impact index
Cases were assigned a clinical grouping in relation to the
nature of their admission. The clinical groupings were:
• Cardiology
• Ear nose and throat
• Gastroenterology
• Gynaecology
• Medicine—general
• Neurology
• Obstetrics
• Oncology
• Orthopaedics
• Psychiatry
• Respiratory
• Surgery—general
• Urology
• Other
An impact index score was calculated for each clinical
grouping. This provides a measure of the potential for
pharmacists to support the clinical workload in that
grouping. The impact index algorithm accommodates both
the workload associated with the clinical group (frequency
of presentation) and the potential proportion of patients that
may be managed by pharmacists.
The impact index was calculated as:
Impactði) ¼ Total cases of CP; IP; IPT in the clinical group
Total number of cases in the clinical group
 Total number of cases per clinical group
total number of cases
ðexcluding thosewhere clinical groupingwas not assignedÞ
The algebraic expression is:
Impact (i) = proportion of workload of grouping (w) 9
proportion ability of pharmacists to manage that clinical
group (a) 9 100
IðiÞ ¼ w a 100
The higher the Impact Index the greater potential for
pharmacists to support the clinical workload in that group
presenting to EDs.
Clinical grouping is not fully synonymous with the usual
case mix of clinical specialties, but rather is a subset of
Emergency Department attendees. Clinical grouping is
used in this study to group presentations to identify clinical
areas suitable for inclusion in advanced clinical practice
training.
Results
18,613 ED cases were observed from 49 sites between
March to July 2015. The age of cases ranged from
0–115 years with a median age of 44 years and mode age
of 27 years (interquartile range 27–67 years). The results
of the categorization of cases from the primary data col-
lection independent prescriber pharmacists are shown in
Table 1 below.
The total number of cases that can be managed by a
pharmacist (including cases where pharmacists specified
what additional training beyond that currently undertaken
Table 1 Summary of the
proportion of cases that
underwent primary
categorizations and counts
during secondary
categorization—type B, per
category
Cases (primary
categorization)
% Counts (secondary
categorization—type B)
%
CP 726 3.90 479 2.40
IP 719 3.90 1784 8.90
IPT 5202 27.90 4937 24.70
MT 11,966 64.30 12,777 64.00
Total 18,613 100 19,977 100
Total pharms 6647 35.70 7200 36.04
CP community pharmacist, IP independent prescriber pharmacist, IPT independent prescriber pharmacist
with additional training, MT medical team only
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by independent prescriber pharmacists—category IPT) is
6647 (35.7%).
Secondary categorization
Secondary categorizations were undertaken by pharmacists
(n = 15), ED physicians (n = 6) and ED nurses (n = 4);
results are shown as ‘counts’ in Table 1 above. By design a
single case may be assigned for secondary categorization
more than once, and by any combination of pharmacists,
physicians or ED nurses. During the study a total of 13,990
cases were secondary categorized at least once, which was
undertaken a total of 19,977 times (described as ‘counts’).
Table 1 shows the sum of all secondary categorizations
expressed in the four categories (CP, IP, IPT, MT)—cal-
culation type B (counts)
Table 2 below shows secondary categorization by
cases—calculation type A (cases).
Secondary categorization, using mean per case [calcu-
lation (type A): award numerical values to ordinal data
(CP = 1, IP = 2, IPT = 3, MT = 4). Take mean of score
for each case, and express each case to one of 7 categories
(CP, CP/IP, IP, IP/IPT, IPT, IPT/MT, MT)].
The most frequent clinical groupings were: general
medicine (36.4%), orthopaedics (16.5%), cardiology (5%),
general surgery (4.9%) and respiratory (4%).
The clinical groupings where pharmacists can poten-
tially have the highest impact are listed in Table 3 below.
The level of agreement between the primary categoriz-
ers (Pharmacist Independent prescriber data collectors) and
physician secondary-categorizers was calculated on a case
by case basis. A kappa statistic of 0.26 (standard error
0.011, with a 95% confidence interval of 0.24–0.28) was
obtained—indicating a fair agreement. See Table 4 for a
cross-tabulation of the primary versus doctor secondary-
categorizer. Exact agreement of the category on a case-by-
case basis was obtained in 60.1% of cases. If category is
considered as ordered, disagreement by more than one
category occurred in just 10.6% of cases. Overall the total
cases categorized to a pharmacist (sum of CP, IP and IPT)
by secondary categorization physicians was 1667 from
4421 (37.7%)—primary categorization of the same cases to
a pharmacist category is 1659 (37.5%).
Regional analysis of the data
The categorization data in different regions varied con-
cerning pharmacists’ potential to manage ED patients, with
results ranging from 16.1 to 43%—with the West Midlands
being a clear outlier according to their primary
categorization.
The Pearson Chi square test comparing pharmacist-
categories (combined) across regions gave a value of
365.533, DF = 10, with a p value\0.001.
Table 5 below shows the summary regional data.
Figures 1 and 2 shows the percentage of ED cases that
were deemed manageable by a pharmacist per region
(primary-categorization and secondary-categorization
respectively).
Training needs content analysis
The training needs described by the primary categorizers
(primary categorizers from 46 sites provided suggestions as
free text) were considered using content analysis, and four
main themes were identified. These are:
Table 2 Summary of cases that
underwent secondary
categorization per category
Cases %
CP 246 1.80
CP/IP 33 0.20
IP 794 5.70
IP/IPT 339 2.40
IPT 3716 26.60
IPT/MT 828 5.90
MT 8034 57.40
Total 13,990 100
Total pharms 5128 36.70
These are mean values as some
cases were categorized by more
than one secondary categorizer
(calculation type-A)
CP community pharmacist, IP
independent prescriber pharma-
cist, IPT independent prescriber
pharmacist with additional
training, MT medical team only
Table 3 Top 5 impact index
clinical groupings determined
from the primary
categorizations (clinical groups
that will be impacted the most
by having pharmacist roles
extended through ACP training)
Total cases Total cases
P
CP ? IP ? IPT Impact index
Medicine-general 6774 2212 13.2
Orthopaedics 3072 1627 9.7
Respiratory 751 308 1.8
Ear, nose and throat 513 276 1.6
Gastroenterology 723 212 1.3
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1. Clinical examination and assessment (42 sites,
n = 4510)
2. Diagnostic skills (36 sites, n = 1381)
3. Medical management and treatment (46 sites,
n = 1236)
4. Training course component (16 sites, n = 359)
The most frequent top 10 subthemes for each of the four
mains themes are described in Tables 6, 7, 8 and 9 below.
Discussion
This study found that approximately 1 in 13 of recorded
ED attendee cases (7.8%) were considered manageable by
pharmacists with existing training (CPs and IPs combined).
This rises to a maximum of 36% if pharmacists are given
further advanced clinical practice training (CP, IP and IPT
combined) as identified by the study respondents.
An additional outcome measure evaluated during the
course of the study was which particular clinical groups
within the ED would benefit from having a pharmacist
manage that group, based on the calculated Impact Index.
The Impact Index was defined to be sensitive to both the
pharmacist’s potential to manage the cases, and the
workload of that group. General Medicine and Orthopae-
dics were found to have the highest Impact Index. To
enable pharmacists to best support the clinical workload of
ED further advanced clinical practice training should focus
on these two clinical areas, and if achieved would enable
Advanced Clinical Practitioner Pharmacists (ACP-Phar-
macists) to manage 27% of all ED attendees.
This study is the first published work to evaluate the
potential of future ACP-Pharmacists within EDs—working
beyond traditional clinical pharmacist roles. This study
estimates for the first time the proportion of ED attendees
ACP-Pharmacists may be able to manage, when situated
within the ED, and as part of the multi-disciplinary team.
Other clinical professions who have ACP status such as
Advanced Nurse Practitioners (ANP) and Paramedic
Table 4 Comparison of the pharmacist primary and doctor sec-
ondary-categorizations of cases
Secondary physician categorization
CP IP IPT MT Total
Primary pharmacist categorization
CP 35 53 43 38 169
IP 21 64 45 75 205
IPT 65 183 476 561 1285
MT 62 186 434 2080 2762
Total 183 486 998 2754 4421
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Practitioners (PP) have a long establish role in clinical
practice, however the body of published evidence sup-
porting these roles is limited. The only published study
which has evaluated the proportion of cases that ANPs can
manage (one hospital site over 8 months) found that 20%
of all ED cases classified as ‘minor’ (1577/7768) could be
managed by the nurse [14]. The evidence base for PPs
showed via a randomized controlled trial that they were
key in preventing hospital admission to ED for older adults
by being part of the ambulance team [15]. To date there are
no published studies considering the role of PPs working
within the ED.
This study builds on and adds generalizability to the
previous pilot study conducted in the West Midlands. The
pilot study found that 45% of ED attendees were poten-
tially manageable by pharmacists across the two study sites
[12], which is higher than the overall findings of this pre-
sent national study (36%). However, the proportion of
cases that were considered manageable by pharmacists
with current training (CPs and IPs) was 1 in 13 for this
study, which is similar to the pilot study proportion of 1 in
12 [12].
The results show that the proportion of cases deemed to
be manageable by pharmacists according to primary cate-
gorization vary from region to region—range 16.1–41.7%,
mean 35.7% (95% CI 35.0–36.4%). Interestingly sec-
ondary categorization gives a narrower range—
31.1–41.5%, mean 36.7% (95% CI 35.85–37.45%), which
may indicate an outlier amongst the primary categorizers.
Although pharmacist independent prescribers have the
same qualification and must have at least 2 years post-
registration experience, this does not fully standardize the
data categorization across the 49 sites. Years of experience
prior to becoming a prescriber may vary.
Current literature indicates that the work of hospital
pharmacists in the EDs of the UK have been limited to
traditional pharmacy roles. These include: medicines rec-
onciliation for high risk patients, transcription of drug
charts, increasing patient-own-drugs use, reviewing medi-
cation and direct support of transfer of changed medicines
information on discharge from the ED, e.g. liaising with
the family physician, community pharmacist and care
homes [16]. In the United States of America (USA), the
roles of the pharmacist in the ED are a collaborative sup-
portive role and mainly involve medicines management,
medicines reconciliation, educating and counseling patients
and carers on safe and effective use of their medication.
They provide direct patient care, but only as part of the
interdisciplinary emergency care team [16, 17]. Our study
suggests that pharmacists with additional training can
undertake clinical management of a wide range of patients
as part of the multi-disciplinary ED workforce.
Limitations
Due to the size of the study, it was not feasible in terms of
resources to conduct the secondary categorization by direct
observation of each case prior to making a clinical judge-
ment. However 75% of cases were categorized twice (both
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Fig. 2 Secondary categorization percentage of cases manageable by
the pharmacist (with 95% CI)
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primary and secondary categorization). The method of
secondary categorization (summary anonymized data) was
validated in a previous pilot study. This present study
recruited 63 pharmacist independent prescribers to observe
cases within the ED and judge whether these were man-
ageable by a pharmacist (n = 18,613, 400 cases per site).
For sites with more than 1 independent prescriber data
collector, the 400 cases were shared across the data
collectors, with one data collector per observation. It would
not have been feasible to ask the data collectors to see the
patients and manage them in real time. Future studies may
include identifying the contribution Advanced Clinical
Practitioner pharmacists can actually make towards
managing the workload in EDs once training has been
completed; and the in-practice experience needed to ensure
clinical competence.
Table 6 Clinical examination
and assessment (42 sites,
n = 4510)
Subtheme (top 10) Number of categorizers involved in
providing training needs information
Number of times
suggested (n)
1. X-ray request and interpretation 31 1428
2. Body examination (e.g. external body) 37 959
3. Clinical examination and assessment 12 295
4. Clinical skills 2 266
5. Neurological assessment 20 220
6. Paediatrics 17 137
7. Chest examination 27 132
8. Respiratory assessment or examination 15 93
9. Eye examination 18 92
10. Observations 5 76
Table 7 Diagnostic skills (36
sites, n = 1381)
Subtheme (top 10) Number of categorizers involved in
providing training needs information
Number of times
suggested (n)
1. ECG 23 546
2. Bloods 14 426
3. Urine testing 10 258
4. Arterial blood gas interpretation 4 22
5. Differential diagnosis 4 20
6. Troponin T 4 12
7. D-dimer test request 4 11
8. CT Scan interpretation 2 7
9. Blood pressure 5 6
10. Doppler 2 5
Table 8 Medical management
and treatment (46 sites,
n = 1236)
Subtheme (top 10) Number of categorizers involved in
providing training needs information
Number of times
suggested (n)
1. Trauma and injury management 14 136
2. Wound care 16 109
3. Analgesia 3 107
4. Paediatric management 13 62
5. Fracture management 7 57
6. Minor illnesses 3 42
7. Pain management 7 37
8. Nosebleeds 7 33
9. Respiratory treatment 7 33
10. Skin conditions 7 32
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This study did not assess in detail cases managed by the
medical team that could not be resolved without the need
of a clinical contribution by a pharmacist, e.g. cases where
the medical team would contact a pharmacist for advice to
resolve a case.
Conclusion
In summary, primary categorization of 18,613 ED cases
confirms the potential for pharmacists (all categories) to
clinically manage up to 36% of ED attendees. With
existing training (CPs and IPs) pharmacists can potentially
manage 8% of ED cases. Further training aligned to the
Advanced Clinical Practice training pathway (IPTs—Ad-
vanced Clinical Practice Pharmacists) increases the
potential of pharmacists to manage a further 28% of cases.
Secondary categorization of the data (a total of 75%,
n = 13,990) supports the validity of the primary catego-
rization findings. Impact Index calculations suggest that
pharmacists with advanced training (IPTs—Advanced
Clinical Practice pharmacists) may be most usefully trained
in general medicine and orthopaedics/minor trauma. If
training were to concentrate on the two areas with the
highest Impact Index (probably achievable with 12 months
advanced clinical training) then, (achievable) IPT becomes
19%, i.e. pharmacists overall could manage 27% of cases
attending ED. In order for pharmacists to manage cases,
they require clinical examination assessment skills as well
as diagnostic skills to broaden and extend their role and
case management potential.
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